Tenascin-C: A novel mediator of hepatic ischemia and reperfusion injury

Hepatology

Volumn 54, Issue 6, 2011, Pages 2125-2136

  Kuriyama, Naohisa ^a   Duarte, Sergio ^a   Hamada, Takashi ^a   Busuttil, Ronald W ^a   Coito, Ana J ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CXCL2 CHEMOKINE; CYCLINE; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; TENASCIN; TOLL LIKE RECEPTOR 4; TRANSFERASE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; ENZYME SYNTHESIS; LEUKOCYTE; LEUKOCYTE MIGRATION; LIVER INJURY; LIVER ISCHEMIA; LIVER REGENERATION; MALE; MOUSE; NEUTROPHIL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY;

ANIMALS; ANTIGENS, CD31; CASPASE 3; IN SITU NICK-END LABELING; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIVER; LIVER REGENERATION; MATRIX METALLOPROTEINASE 9; MICE; REPERFUSION INJURY; TENASCIN; TOLL-LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE-1;

EID: 82455168058     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24639     Document Type: Article

References (51)

1. Howard TK, Klintmalm GB, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 1990; 49: 103-107.
2. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. HEPATOLOGY 2000; 32: 169-173.
3. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651-663.
4. Coito AJ, Kupiec-Weglinski JW, Busuttil RW. Extracellular matrix and organ transplantation. In: Wilkes DS, Burlingham WD, editors. Immunobiology of Organ Transplantation. New York: Kluwer Academic/Plenum; 2004: 576-589.
5. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5.
6. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-780.
7. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005; 37: 1066-1083.
8. Tanaka K, Hiraiwa N, Hashimoto H, Yamazaki Y, Kusakabe M. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 2004; 108: 31-40.
9. Hemesath TJ, Stefansson K. Expression of tenascin in thymus and thymic nonlymphoid cells. J Immunol 1994; 152: 422-428.
10. Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, et al. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 2009; 182: 8015-8025.
11. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, et al. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 2007; 211: 86-94.
12. Spring J, Beck K, Chiquet-Ehrismann R. Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments. Cell 1989; 59: 325-334.
13. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009; 3: 287-310.
14. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. J Cell Biol 1997; 137: 755-765.
15. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992; 6: 1821-1831.
16. Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. HEPATOLOGY 2008; 47: 186-198.
17. Chen SW, Park SW, Kim M, Brown KM, D'Agati VD, Lee HT. Human heat shock protein 27 overexpressing mice are protected against hepatic ischemia and reperfusion injury. Transplantation 2009; 87: 1478-1487.
18. Hamada T, Duarte S, Tsuchihashi S, Busuttil RW, Coito AJ. Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am J Pathol 2009; 174: 2265-2277.
19. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326( Pt 1): 1-16.
20. Yadav SS, Sindram D, Perry DK, Clavien PA. Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspase-dependent pathway. HEPATOLOGY 1999; 30: 1223-1231.
21. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 1999; 10: 629-639.
22. Bantel H, Lugering A, Poremba C, Lugering N, Held J, Domschke W, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. HEPATOLOGY 2001; 34: 758-767.
23. Dixon MF, Fulker MJ, Walker BE, Kelleher J, Losowsky MS. Serum transaminase levels after experimental paracetamol-induced hepatic necrosis. Gut 1975; 16: 800-807.
24. Calabrese F, Pontisso P, Pettenazzo E, Benvegnu L, Vario A, Chemello L, et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. HEPATOLOGY 2000; 31: 1153-1159.
25. Patel T, Gores GJ. Apoptosis and hepatobiliary disease. HEPATOLOGY 1995; 21: 1725-1741.
26. Kwon YH, Jovanovic A, Serfas MS, Tyner AL. The Cdk inhibitor p21 is required for necrosis, but it inhibits apoptosis following toxin-induced liver injury. J Biol Chem 2003; 278: 30348-30355.
27. Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci U S A 2007; 104: 17081-17086.
28. Pagano MB, Bartoli MA, Ennis TL, Mao D, Simmons PM, Thompson RW, et al. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci U S A 2007; 104: 2855-2860.
29. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8( Suppl 2): S3.
30. Ramadori G, Moriconi F, Malik I, Dudas J. Physiology and pathophysiology of liver inflammation, damage and repair. J Physiol Pharmacol 2008; 59( Suppl 1): 107-117.
31. Coito AJ. Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury. Curr Opin Organ Transplant 2011; 16: 34-40.
32. Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med 2008; 14: 337-345.
33. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 2010; 184: 2655-2662.
34. Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 2008; 32: 1031-1039.
35. El-Karef A, Kaito M, Tanaka H, Ikeda K, Nishioka T, Fujita N, et al. Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. J Hepatol 2007; 46: 664-673.
36. Settles DL, Kusakabe M, Steindler DA, Fillmore H, Erickson HP. Tenascin-C knockout mouse has no detectable tenascin-C protein. J Neurosci Res 1997; 47: 109-117.
37. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006; 43: S31-S44.
38. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-562.
39. Wallner K, Li C, Shah PK, Wu KJ, Schwartz SM, Sharifi BG. EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 1416-1421.
40. Matsui T, Kinoshita T, Hirano T, Yokota T, Miyajima A. STAT3 down-regulates the expression of cyclin D during liver development. J Biol Chem 2002; 277: 36167-36173.
41. Zhao X, Koshiba T, Nakamura T, Tsuruyama T, Li Y, Bando T, et al. ET-Kyoto solution plus dibutyryl cyclic adenosine monophosphate is superior to University of Wisconsin solution in rat liver preservation. Cell Transplant 2008; 17: 99-109.
42. Neubauer K, Lindhorst A, Tron K, Ramadori G, Saile B. Decrease of PECAM-1-gene-expression induced by proinflammatory cytokines IFN-gamma and IFN-alpha is reversed by TGF-beta in sinusoidal endothelial cells and hepatic mononuclear phagocytes. BMC Physiol 2008; 8: 9.
43. Jaeschke H, Hasegawa T. Role of neutrophils in acute inflammatory liver injury. Liver Int 2006; 26: 912-919.
44. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM, et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci U S A 2005; 102: 431-436.
45. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245-257.
46. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.
47. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, Garcia-Arroyo A, Garcia-Sanchez A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-241.
48. Khan KM, Falcone DJ. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem 1997; 272: 8270-8275.
49. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 1994; 5: 439-453.
50. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C up-regulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 2003; 105: 53-60.
51. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007; 115: 1599-1608.